COMMUNIQUÉS West-GlobeNewswire

Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC
05/04/2024
TARA-002 demonstrated a complete response rate of 43% at three months in BCG-Unresponsive /Experienced patients in ongoing NMIBC program TARA-002 demonstrated a complete response rate of 63% at three months in CIS-only [...]
Postponement Annual Shareholders Meeting - Amendment financial calendar
05/04/2024
Postponement Annual Shareholders Meeting - Amendment financial calendar Leuven, BELGIUM – April 5, 2024 – 02:00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today [...]
Leash Biosciences Announces $9.3 Million Seed Financing to Pioneer AI-Driven Medicinal Chemistry
05/04/2024
– Financing will support development of a foundational machine learning model of medicinal chemistry that can accurately predict small molecule drug candidates for any protein – – Releases unprecedented dataset publicly [...]
IntelGenx Updates Status of Buprenorphine Buccal Film ANDA
05/04/2024
SAINT LAURENT, Quebec, April 05, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the “Company” or “IntelGenx”) today announced that its co-developer, Chemo Research SL, through its agent and affiliate, [...]
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/04/2024
SAN DIEGO, April 05, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of [...]
Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73ʳᵈ Annual Scientific Session
05/04/2024
Treatment with Aficamten for 48 Weeks is Associated with Improvements in Clinical Efficacy Endpoints, NYHA Class and Cardiac Biomarkers, Structure and Function SOUTH SAN FRANCISCO, Calif., April 05, 2024 (GLOBE NEWSWIRE [...]
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy
05/04/2024
Established Low Dose as Safe and Tolerable Dose in Current OCU410 Clinical Trial DSMB Approval to Proceed with Medium Dose Cohort Dosing Malvern, Pa., April 05, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the [...]
Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference
05/04/2024
Company presentation and fireside chat on April 11th at 11:45 a.m. ET CAMBRIDGE, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a [...]
Teladoc Health Board of Directors Announces Leadership Transition
05/04/2024
Jason Gorevic to depart the company, effective immediately CFO Mala Murthy appointed acting chief executive Teladoc Health reaffirms guidance PURCHASE, NY, April 05, 2024 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: [...]
HUTCHMED Highlights Data to be Presented at AACR Congress 2024
05/04/2024
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 05, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies [...]
Predicine to Present 15 Liquid Biopsy Studies at AACR 2024
05/04/2024
HAYWARD, Calif., April 05, 2024 (GLOBE NEWSWIRE) -- Predicine, Inc. A leading precision oncology company, announced today that it will present data from 15 ctDNA studies at AACR 2024, spotlighting the clinical utility [...]
Samsung Bioepis Initiates Phase 3 Clinical Trial for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)
05/04/2024
INCHEON, Korea, April 05, 2024 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. today announced the initiation of Phase 3 clinical trial for SB27, the company's proposed biosimilar referencing Keytruda i (pembrolizumab). [...]
CORRECTION -- NeuroVigil, World’s Most Valuable Neurotech Company, Launches in US
05/04/2024
CLOSED 6 BILLION DOLLAR SERIES B DEAL SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Thursday, April 4, 2024 by NeuroVigil, Inc., please note the contact information [...]
Ibogaine By David Dardashti Investigates Impact of Quantum Physics on April 8 Solar Eclipse
05/04/2024
A Unique Opportunity to Experience the Unprecedented Potential of Ibogaine Treatment Based on Quantum Electrodynamics MIAMI, April 04, 2024 (GLOBE NEWSWIRE) -- Ibogaine By David Dardashti has uncovered a unique [...]
Sirona Biochem Announces Close of Private Placement
05/04/2024
VANCOUVER, British Columbia, April 04, 2024 (GLOBE NEWSWIRE) -- Vancouver, British Columbia – April 4, 2024 – Sirona Biochem Corp . (TSX-V: SBM) (Frankfurt: ZSB) (“ Sirona ”) has closed its private placement (Private [...]
Contineum Therapeutics Announces Pricing of Initial Public Offering
05/04/2024
SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- Contineum Therapeutics, Inc. (Contineum), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target [...]
Digicann Ventures Grants Restricted Share Units
05/04/2024
VANCOUVER, British Columbia, April 04, 2024 (GLOBE NEWSWIRE) -- Digicann Ventures Ltd. (“Digicann” or the “Company”) (CSE: DCNN) (OTCPK: AGFAD), a company focused on opportunities within and outside of the cannabis [...]
CORRECTION : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
05/04/2024
(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) PARIS, 05 avr. 2024 (GLOBE NEWSWIRE) -- Ce document corrige et remplace le communiqué de presse diffusé le 4 avril à 16:30 heure de l'Est. Place [...]
Opthea to Participate in the 23ʳᵈ Annual Needham Virtual Healthcare Conference
05/04/2024
MELBOURNE, Australia and PRINCETON, N.J., April 04, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat [...]

Pages